Significance of nuclear factor - kappa beta activation on prostate needle biopsy samples in the evaluation of Gleason score 6 prostatic carcinoma indolence
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018; 103: 356-87. doi: 10.1016/j.ejca.2018.07.005.FerlayJColombetMSoerjomataramIDybaTRandiGBettioMet alCancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018Eur J Cancer20181033568710.1016/j.ejca.2018.07.005Open DOISearch in Google Scholar
Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14: 1165-74. doi: 10.1016/S1470-2045(13)70442-X.Luengo-FernandezRLealJGrayASullivanREconomic burden of cancer across the European Union: a population-based cost analysisLancet Oncol20131411657410.1016/S1470-2045(13)70442-XOpen DOISearch in Google Scholar
Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004; 171: 1393-401. doi: 10.1097/01.ju.0000107247.81471.06CooperbergMRBroeringJMLitwinMSLubeckDPMehtaSSHenningJMet alThe contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registryJ Urol2004171139340110.1097/01.ju.0000107247.81471.0615017184Open DOISearch in Google Scholar
Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095101. doi: 10.1001/jama.293.17.2095AlbertsenPCHanleyJAFineJ20-year outcomes following conservative management of clinically localized prostate cancerJAMA2005293209510110.1001/jama.293.17.209515870412Open DOISearch in Google Scholar
Bangma CH, Roobol MJ. Defining and predicting indolent and low risk prostate cancer. Crit Rev Oncol Hematol 2012; 83: 235-41. doi: 10.1016/j.critrevonc.2011.10.003BangmaCHRoobolMJDefining and predicting indolent and low risk prostate cancerCrit Rev Oncol Hematol2012832354110.1016/j.critrevonc.2011.10.00322033113Open DOISearch in Google Scholar
Karin M, Lin A. NF-κB at the crossroads of life and death. Nat. Immunol 2002; 3: 221-7. doi: 10.1038/ni0302-221KarinMLinANF-κB at the crossroads of life and deathNat. Immunol20023221710.1038/ni0302-22111875461Open DOISearch in Google Scholar
May MJ, Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol 1997; 8: 63-73. doi: 10.1006/scbi.1997.0057MayMJGhoshSRel/NF-kappa B and I kappa B proteins: an overviewSemin Cancer Biol19978637310.1006/scbi.1997.00579299584Open DOISearch in Google Scholar
Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM, et al. Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 2006; 12: 5741-5. doi: 10.1158/1078-0432.CCR-06-0330LessardLKarakiewiczPIBellon-GagnonPAlam-FahmyMIsmailHAMes-MassonAMet alNuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastasesClin Cancer Res2006125741510.1158/1078-0432.CCR-06-033017020979Open DOISearch in Google Scholar
Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, et al. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005; 93: 1285-94. doi: 10.1038/sj.bjc.6602851Domingo-DomenechJMelladoBFerrerBTruanDCodony-ServatJSauledaSet alActivation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapseBr J Cancer20059312859410.1038/sj.bjc.6602851236150916278667Open DOISearch in Google Scholar
Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, et al. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immuno-reactivity with disease recurrence. Clin Cancer Res 2004; 10: 2466-72. doi: 10.1158/1078-0432.ccr-0543-3RossJSKallakuryBVSheehanCEFisherHAKaufmanRP JrKaurPet alExpression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immuno-reactivity with disease recurrenceClin Cancer Res20041024667210.1158/1078-0432.ccr-0543-315073126Open DOISearch in Google Scholar
Setlur SR, Royce TE, Sboner A, Mosquera JM, Demichelis F, Hofer MD, et al. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 2007; 67: 10296-303. doi: 10.1158/1078-0432. ccr-0543-3SetlurSRRoyceTESbonerAMosqueraJMDemichelisFHoferMDet alIntegrative microarray analysis of pathways dysregulated in metastatic prostate cancerCancer Res2007671029630310.1158/1078-0432.ccr-0543-315073126Open DOISearch in Google Scholar
Park MH, Hong JT. Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells 2016; 5: E15. doi: 10.3390/cells5020015.ParkMHHongJTRoles of NF-κB in cancer and inflammatory diseases and their therapeutic approachesCells20165E1510.3390/cells5020015493166427043634Open DOISearch in Google Scholar
Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005; 93: 1019-23. doi: 10.1038/sj.bjc.6602796LessardLBeginLRGleaveMEMes-MassonAMSaadFNuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical studyBr J Cancer20059310192310.1038/sj.bjc.6602796236168716205698Open DOISearch in Google Scholar
Gannon PO, Lessard L, Stevens LM, Forest V, Bégin LR, Minner S, et al. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. Eur J Cancer 2013; 49: 2441-8. doi: 10.1016/j. ejca.2013.02.026GannonPOLessardLStevensLMForestVBéginLRMinnerSet alLarge-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancerEur J Cancer2013492441810.1016/j.ejca.2013.02.02623541563Open DOISearch in Google Scholar
Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, et al. NIH State-of-the-Science Conference Statement: role of active surveillance in the management of men with localized prostate cancer. NIH Consens State Sci Statements 2011; 28: 1-27. PMID: 23392076GanzPABarryJMBurkeWColNFCorsoPSDodsonEet alNIH State-of-the-Science Conference Statement: role of active surveillance in the management of men with localized prostate cancerNIH Consens State Sci Statements201128127PMID: 23392076Search in Google Scholar
Lucia MS, Bostwick DG, Somerville MC, Fowler IL, Rittmaster RS. Comparison of classic and international society of urological pathology 2005 modified Gleason grading using needle biopsies from the reduction by dutasteride of prostate cancer events (REDUCE) trial. Arch Pathol Lab Med 2013; 137: 1740-6. doi: 10.5858/arpa.2012-0447-OALuciaMSBostwickDGSomervilleMCFowlerILRittmasterRSComparison of classic and international society of urological pathology 2005 modified Gleason grading using needle biopsies from the reduction by dutasteride of prostate cancer events (REDUCE) trialArch Pathol Lab Med20131371740610.5858/arpa.2012-0447-OA24283854Open DOISearch in Google Scholar
Komisarenko M, Martin LJ, Finelli A. Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes. Transl Androl Urol 2018; 7: 243-55. doi: 10.21037/tau.2018.03.02KomisarenkoMMartinLJFinelliAActive surveillance review: contemporary selection criteria, follow-up, compliance and outcomesTransl Androl Urol201872435510.21037/tau.2018.03.02591153429732283Open DOISearch in Google Scholar
McCormick BZ, Mahmoud AM, Williams SB, Davis JW. Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian J Urol 2019; 35: 6-17. doi: 10.4103/iju.IJU_355_18McCormickBZMahmoudAMWilliamsSBDavisJWBiochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategiesIndian J Urol20193561710.4103/iju.IJU_355_18633458330692719Open DOISearch in Google Scholar
